RNA-Seq based gene expression profiling of baseline and on-treatment breast tumors to predict response to HER2-directed therapy, without chemotherapy (TBCRC026)

被引：0
|
作者：
Hennessy, Maeve
Fernandez, Aranzazu
Huang, Chiung Yu
Cimino-Mathews, Ashley
Denbow, Rita
Abramson, Vandana G.
Rimawi, Mothaffar F.
Specht, Jennifer M.
Storniolo, Anna Maria
Valero, Vicente
Vaklavas, Chris
Winer, Eric P.
Krop, Ian E.
Wolff, Antonio C.
Wahl, Richard L.
Thompson, E. Aubrey
Stearns, Vered
Perou, Charles
Carey, Lisa A.
Connolly, Roisin M.
机构：
[1] Canc Res UCC, Cork, Ireland
[2] Lineberger Comprehens Ctr, Chapel Hill, NC USA
[3] Univ Calif San Francisco, San Francisco, CA USA
[4] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Sidney, BC, Canada
[6] Vanderbilt Univ, Nashville, TN USA
[7] Baylor Coll Med, Houston, TX USA
[8] Univ Washington, Seattle, WA USA
[9] Melvin & Bren Simon Canc Ctr, Indianapolis, IN USA
[10] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol Dept, Houston, TX USA
[11] Univ Alabama Birmingham, Birmingham, AL USA
[12] Yale Canc Ctr, New Haven, CT USA
[13] Washington Univ, Mallinckrodt Inst Radiol, Sch Med, St Louis, MO USA
[14] Mayo Clin Comprehens Canc Ctr, Jacksonville, FL USA
[15] Weill Cornell Med, New York, NY USA
[16] Univ North Carolina Chapel Hill, Chapel Hill, NC USA
[17] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
530
引用
收藏
页数：1
相关论文
共 4 条
  • [1] Evaluation of a composite PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant HER2-directed therapy in early breast cancer (TBCRC026)
    Hennessy, M. A.
    Cimino-Mathews, A.
    Carter, J.
    Kachergus, J.
    Ma, Y.
    Leal, J.
    Solnes, L.
    Abramson, V.
    Carey, L. A.
    Rimawi, M.
    Specht, J.
    Storniolo, A. M.
    Vaklavas, C.
    Wolff, A. C.
    Wahl, R.
    Perez, E. A.
    Huang, C-Y.
    Stearns, V.
    Thompson, A.
    Connolly, R. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S316 - S316
  • [2] A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
    Hennessy, Maeve A.
    Cimino-Mathews, Ashley
    Carter, Jodi M.
    Kachergus, Jennifer M.
    Ma, Yaohua
    Leal, Jeffrey P.
    Solnes, Lilja B.
    Abramson, Vandana G.
    Carey, Lisa A.
    Rimawi, Mothaffar
    Specht, Jennifer
    Storniolo, Anna Maria
    Vaklavas, Christos
    Krop, Ian
    Winer, Eric
    Denbow, Rita
    Valero, Vincente
    Wolff, Antonio C.
    Wahl, Richard L.
    Huang, Chiung-Yu
    Stearns, Vered
    Thompson, E. Aubrey
    Connolly, Roisin M.
    BREAST, 2025, 81
  • [3] Evaluation of gene expression by RNA-seq after single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast cancer.
    Galanina, Natalie
    Sprecher, Emmet
    Bossuyt, Veerle
    Sarkar, Sudipa
    Krop, Ian E.
    Winer, Eric
    Tuck, David P.
    Bruce, Can
    Harris, Lyndsay
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Breast tumor xenografts of luminal subtype switch to the ERBB2+molecular subtype in response to endocrine therapy: Gene expression profiling may not predict pathways of resistance in pretreatment tumors
    Creighton, Chad J.
    Massarweh, Suleiman
    Huang, Shixia
    Tsimelzon, Anna
    Hilsenbeck, Susan G.
    Osborne, C. K.
    Schiff, Rachel
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3484S - 3485S
1